Unitary Patent: Stop talking, start planning

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Unitary Patent: Stop talking, start planning

Today is a turning-point for patents in Europe. The Court of Justice of the EU has ruled on Spain’s challenge to the Unitary Patent Regulations, and we need to start looking forward to how the new system will work in practice

CJEU judges

As we reported this morning, the Grand Panel of the Court (pictured right) dismissed every aspect of Spain’s dual challenge, the second time the country has queried the Unitary Patent plan. That must remove any remaining uncertainties over the legal basis of the EU scheme, even if it doesn’t (yet) persuade the Spanish government to sign up.

The opponents of the proposed system, led by the Spanish government, had some strong and sincerely held arguments against it. The Court has firmly, clearly and finally rejected these, as the Advocate General did last year.

No doubt some critics will remain unpersuaded by its judgments, will continue to criticise the proposed system and may even seek further reviews at the European Court of Human Rights.

But surely now is the time for everyone to take a deep breath and say: the CJEU has clearly spoken, much of the work is underway and patent applicants (and third parties) need certainty. Whatever your personal views about the merits of what is proposed, it is time to put them aside and try to make the system work in practice.

Above all that means: How much will it cost? When will it come into effect? And should I use the system for some or all of my patents?

EU flag

We now need to see some more activity from governments and the EPO to clarify renewal, opt-out and court fees, the final rules of procedure and judicial appointments. The recent proposals on fees, while not as low as most users would like, are at least a starting point, and we understand that there may be further announcements on the other fees within the next week.

I know from speaking to in-house counsel that news on costs cannot come soon enough: many are already working on budgets that could be affected by the Unitary Patent (for example, the opt-out fees) and need to make spending decisions.

Patent practitioners in Europe also have a duty to their clients, and to the public at large, to make the system work as efficiently and fairly as possible. That includes building expertise, engaging in consultations and promoting understanding.

We’ve had several years or debate about the advantages and shortfalls of the Unitary Patent and UPC and what is proposed certainly does not please everybody. But the time for arguing is now over, and the time for planning how to make it work in practice work must begin in earnest.

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article